ARTHROPLASTY
ISAKOS 2015: 10 day Rivaroxaban reduces venous thromboembolism 3 months after TKA
268 patients (330 knees) undergoing primary TKA were randomized into three groups, receiving either rivaroxaban (10mg) for 7 or 10 days post operation, or low molecular weight heparin (5000IU) for 2 days followed by aspirin 100mg for 5 days. The purpose of the study was to analyze the incidence of venous thromboembolism among groups to determine the safety and efficacy of prophylaxis regimens, over 3 months post-surgery. Results indicated that 10 day rivaroxavan treatment was superior in reducing VTE incidence, than 7 day treatment or heparin and aspiring treatment, without increasing complications.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
